Making Pain Relief Affordable – Or Abuse Cheaper?
This article was originally published in RPM Report
Executive Summary
There are many arguments against generics of opioids, especially if you’re Purdue Pharma. Here’s a new one: they’re lower the cost for abusers.
You may also be interested in...
DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
Medicare Proposes Earlier Deadline For Rx Add-On Payment Candidates
Starting in fiscal year 2025, products would need to meet an earlier, May deadline for FDA approval in order to be eligible for enhanced payments in the Hospital Inpatient Prospective Payment System (IPPS). The change would give CMS more to handle the surge in NTAP applications.
Drug Shortages Back In US Congressional Spotlight
Drug shortages were a significant focus of legislative attention in the US before the COVID-19 pandemic, and Congress is not likely to drop the issue now that the public health emergency is winding down.